Stockscreener 앱 받기
129.11
1.39%
1.77
시간 외 거래:
134.00
4.89
+3.79%
Guardant Health Inc 주식(GH)의 최신 뉴스
[Form 4] Guardant Health, Inc. Insider Trading Activity - Stock Titan
GH (GH) affiliate Kumud Kalia notifies proposed sale of 5,000 shares - Stock Titan
GH (NASDAQ: GH) amendment: affiliate sold 5,000 shares for $652,030 - Stock Titan
Kumud Kalia sells shares; GH (NASDAQ: GH) Form 144 lists dates and proceeds - Stock Titan
The Technical Signals Behind (GH) That Institutions Follow - Stock Traders Daily
Guardant Health Inc. (NASDAQ:GH) Shines as a Top Minervini Trend Template and High Growth Momentum Pick - ChartMill
What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook - Kavout
Guardant rated new outperform at RBC on catalysts, growth prospects - MSN
Top Guardant Health Executive Makes Major Insider Move - TipRanks
Guardant Health CIO Kalia sells $652,030 in company stock By Investing.com - Investing.com Australia
Guardant Health CIO Kalia sells $652,030 in company stock - Investing.com
Insider Sell: Kumud Kalia Sells 5,000 Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health Chief Information Officer Sold Shares Worth Over $652K - TradingView
Guardant Health (GH) CIO Kumud Kalia sells 5,000 shares in open market - Stock Titan
Guardant Health (GH) Receives Outperform Rating from RBC Capital Markets - GuruFocus
Guardant Health rated new Outperform at RBC (GH:NASDAQ) - Seeking Alpha
Guardant Health Set to Benefit From Genomic Profiling Growth, RBC Says - Moomoo
RBC Capital Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $185 - Moomoo
RBC Capital Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $185 - Moomoo
RBC Capital initiates Guardant Health stock coverage with outperform rating - Investing.com
RBC Capital initiates Guardant Health stock coverage with outperform rating By Investing.com - Investing.com Canada
GH Receives FDA Approval for Guardant360 CDx as Companion Diagno - GuruFocus
Guardant Health wins FDA approval for HER2 lung cancer test By Investing.com - Investing.com Australia
Guardant Health wins FDA approval for HER2 lung cancer test - Investing.com
Guardant Health, Inc. Announces FDA Approval Of Guardant360 CDx As Companion Diagnostic For Boehringer Ingelheim?s HERNEXEOS - marketscreener.com
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS - The Joplin Globe
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health co-CEO Helmy Eltoukhy sells $12.6m in stock By Investing.com - Investing.com South Africa
Guardant Health Insider Sold Shares Worth $12,629,969, According to a Recent SEC Filing - Moomoo
Insider Sell: Michael Bell Sells 2,000 Shares of Guardant Health Inc (GH) - GuruFocus
GH Maintained by Mizuho -- Price Target Raised to $175 - GuruFocus
Guardant Health CFO Michael Bell sells $257,240 in company shares By Investing.com - Investing.com Nigeria
Guardant Health co-CEO Helmy Eltoukhy sells $12.6m in stock - Investing.com India
Guardant Health CFO Michael Bell sells $257,240 in company shares - Investing.com
Guardant Health (NASDAQ: GH) co-CEO’s trust sells 100,000 shares in open market - Stock Titan
Guardant Health (GH) CFO sells 2,000 shares in open-market trade - Stock Titan
HHS indicates skepticism on international cancer risk assessments - Seeking Alpha
Mizuho raises Guardant Health stock price target to $175 on FDA approval By Investing.com - Investing.com South Africa
Mizuho raises Guardant Health stock price target to $175 on FDA approval - Investing.com Canada
Why Grail Could Be the Sleeper Stock Everyone's About to Notice - The Motley Fool
Guardant Health, Inc. (GH) Stock Analysis: Navigating a 9.14% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Goldman Sachs Initiates Guardant Health(GH.US) With Buy Rating, Announces Target Price $165 - Moomoo
Insider Sale: Director at $GH Sells 9,294 Shares - Moomoo
Insider Sell: Steve Krognes Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health director Steve Krognes sells $1.23m in stock By Investing.com - Investing.com South Africa
Guardant Health director Steve Krognes sells $1.23m in stock - Investing.com
Guardant Health (NASDAQ: GH) director sells 9,294 shares in open-market trade - Stock Titan
Guardant Health, Inc. (GH) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
GH Initiates Coverage On Goldman Sachs -- Rating Set to Buy - GuruFocus
GH (Nasdaq) Form 144: Brokered RSU sale schedule via Stifel Nicolaus - Stock Titan
Guardant Health (NASDAQ: GH) Form 144: 2,000 shares listed, 3,000 sold - Stock Titan
How The Guardant Health (GH) Investment Story Is Evolving As Expectations Stay Unchanged - Yahoo Finance
1.63%
2.88%
자본화:
|
볼륨(24시간):